Background: Triplet combination chemotherapy has the potential to improve the prognosis of patients with unresectable gastric cancer. We conducted a phase I trial of triplet combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 (PCS) for unresectable gastric cancer.
Patients And Methods: Patients with metastatic or incurable disease were enrolled. S-1 was administered on days 1-14. Paclitaxel and cisplatin were infused on days 1 and 15. The starting doses of paclitaxel and cisplatin were 100 and 20 mg/m(2), respectively. Dose levels of paclitaxel and cisplatin were escalated as follows: 120 and 20 mg/m(2), respectively (level 2); 120 and 30 mg/m(2), respectively (level 3). End-points: Dose-limiting toxicities included grade 3 nausea, vomiting, and general fatigue, and grade 4 febrile neutropenia. The maximum tolerated dose and recommended dose were established at level 3 and level 2, respectively.
Conclusion: Although further clinical trials are recommended to more thoroughly evaluate safety and efficacy, PCS appears to be an excellent candidate for a standard treatment strategy for unresectable gastric cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The surgical safety margin after neoadjuvant chemotherapy combined with nimotuzumab leading to tumor regression.
J Chin Med Assoc
December 2024
Department of Stomatology, The Fourth Hospital of Hebei Medical University, Hebei Tumor Hospital, Hebei, China.
Background: To investigate the effect of nimotuzumab (N) combined with nab-paclitaxel, cisplatin, and fluorouracil (APF) neoadjuvant chemotherapy on the surgical margin.
Methods: 55 patients were divided into three groups: neoadjuvant chemotherapy and surgery group (G1, 15 cases), chemotherapy and surgery group (G2 group, 20 cases), and surgery group (G3 group, 20 cases). Tissue samples of the tumor core zone (P0), adjacent (P1, 3-5mm from tumor), distal adjacent (P2, 7-10mm from tumor), and surgical margin (P3, 15mm from tumor) were collected.
CD8 + T-Cell-Related Genes: Deciphering Their Role in the Pancreatic Adenocarcinoma TME and Their Effect on Prognosis.
Dig Dis Sci
November 2024
Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao University, No. 59 Haier Road, Qingdao, 266000, Shandong, China.
Article Synopsis
- Immunotherapy and targeted therapies struggle to effectively treat pancreatic adenocarcinoma (PAAD) due to its unique tumor microenvironment (TME), highlighting the importance of CD8+ T cells in this context.
- * Researchers utilized gene coexpression network analysis and algorithms to assess PAAD data from The Cancer Genome Atlas, aiming to understand CD8+ T-cell infiltration and develop a risk score model for patient prognosis.
- * A validated risk model, based on five CD8-related genes, indicated that patients in a low-risk group had better survival outcomes, while also finding correlations between tumor mutation burden and immune function associated with the risk score.
Diaphragm epithelioid hemangioendothelioma: a rare case report.
BMC Geriatr
November 2024
Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, The Second Clinical Medical College, Chengdu Fifth People's Hospital, Affiliated Fifth People's Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Article Synopsis
- * A case study details a 75-year-old male with symptoms like cough and chest tightness who was diagnosed with Diaphragm EHE after a biopsy, and despite receiving chemotherapy and targeted therapy treatment, he experienced disease progression.
- * The study concludes that EHE associated with pleural effusion tends to progress rapidly, indicating challenges in managing such cases.
Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series.
J Dermatol
January 2025
Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Article Synopsis
- Immune checkpoint inhibitors (ICIs), like pembrolizumab (PEM), are effective against tumors but can cause serious skin side effects (cutaneously adverse events or CAEs), especially when used in combination therapies.
- Severe CAEs may require stopping the immunotherapy, and the risk is higher when ICIs are used with other treatments compared to when they are used alone.
- A case study of 19 women with advanced cervical cancer highlighted the occurrence of severe CAEs, including erythema multiforme and anaphylaxis, stressing the need for tight monitoring of skin reactions during PEM combination therapy to ensure patient safety.
Boosting Antioxidant Defense: The Effect of Astaxantin on Superoxidase Dismutase and Malondialdehyde Reduction in Patients with Head and Neck Cancer Receiving Cisplatin Chemotherapy.
Asian Pac J Cancer Prev
October 2024
Division of Hematology Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Kariadi Hospital, Indonesia.
Background: Superoxide dismutase (SOD) can be decreased and malondialdehyde (MDA) can be increased in patients with head and neck cancer (HNC) as a result of reactive oxygen species (ROS) brought on by cisplatin. Astaxanthin is one of the external antioxidants required to combat ROS by raising SOD and lowering MDA. The purpose of this study is to demonstrate that astaxanthin can raise SOD and lower MDA in patients with HNC caused by cisplatin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!